UK rare disease companies call for leadership in supporting access to new treatments

Working together through their trade body, the BioIndustry Association (BIA), a group of British rare disease drug developers is calling for the UK to lead greater collaboration between stakeholders, and uptake of best practice both in the UK and internationally, to improve access to new treatments for patients.

The call from the BIA’s Rare Disease Industry Group (RDIG) is informed by a new report by the BIA, with research provided by global consultancy firm PwC, which has highlighted the progress that has been made in improving access to rare disease treatments in the UK, and the challenges that remain.

The report, ‘Evaluating patient access to rare disease treatments’: Insights from the UK and beyond, is based on a series of interviews and focus groups with key stakeholders in the UK rare disease space, including NHS England, the National Institute for Health and Care Excellence (NICE), patient groups, clinicians, and industry.